Peptides for men in 2025: hype check on recovery and aging claims

What did @shesfuntho2 actually say?

The creator shares a conversation with a man dealing with a long-standing college injury. She says he previously had access in the UK to something that "over here is a veterinary medicine" and helped with inflammation. She mentions he is now researching what she calls the "Wolverine" stack, something she refers to as "TERS," and repeatedly references "Tessa Morellen" or "Tessa Morell" when she appears to mean testosterone or CJC-1295 with ipamorelin. She also brings up CJC-1295 specifically in the context of muscle building for injury protection.

The transcript is hard to follow. Several peptide names are garbled beyond recognition, and it is not always clear whether she is describing her own protocol, his research, or a product sold on her platform. She frames the whole thing as education, not medical advice, but the specificity of her recommendations tells a different story.

Does the science back this up?

Some of it does, partially. TB-500 (thymosin beta-4), which is almost certainly the "veterinary medicine" she is referencing, has real science behind it, just not in humans yet. CJC-1295 with ipamorelin has a more developed evidence base for growth hormone secretion. The rest gets murky fast.

TB-500 is FDA-designated as a research compound and is not approved for human use in the US. The peptide does show anti-inflammatory and tissue-repair activity in animal models. A 2010 study by Goldstein et al. in the Annals of the New York Academy of Sciences described thymosin beta-4 as a potent actin-sequestering molecule with wound healing properties, but the human clinical trial data remains thin. CJC-1295 combined with ipamorelin stimulates growth hormone release through two complementary pathways. A study by Teichman et al. (2006, Journal of Clinical Endocrinology and Metabolism) confirmed sustained GH elevation with CJC-1295, though the subjects were healthy adults, not injured men over 40 recovering from chronic orthopedic issues. Extrapolating that to injury recovery is a stretch the research does not yet support.

What did they get wrong (or right)?

She got one thing right: TB-500 is effectively unavailable for legal human use in the US and is classified for veterinary or research purposes only. That framing is accurate, even if she stumbles through explaining it.

What she gets wrong is more significant. The "Wolverine" stack, a popular biohacking combo typically including BPC-157 and TB-500, is presented as a near-obvious choice for this man's injury without any discussion of his medical history beyond "old college injury" and "inflammation." BPC-157 has compelling rodent data, including a 2016 study by Sikiric et al. in Current Pharmaceutical Design showing accelerated soft tissue healing in animal models, but zero completed human randomized controlled trials. Presenting this to a general audience as a researched solution for a specific injury crosses a line. She also appears to confuse multiple peptide names throughout the video, which makes it impossible to evaluate some of her specific claims. "TERS" does not correspond to any recognized peptide in clinical or research literature.

What should you actually know?

If you are a man over 40 with a chronic injury and you are researching peptides, here is what the evidence actually supports at this point. BPC-157 and TB-500 show real promise in animal tissue repair models, but neither has cleared human clinical trials. That gap matters. Animal data does not always translate, and dosing, delivery method, and individual pharmacokinetics are all unknowns without human trial data.

CJC-1295 with ipamorelin has the strongest human evidence base in this category for growth hormone modulation, but that evidence is mostly in healthy adults and is not specifically tied to injury recovery outcomes. The FDA does not approve these compounds for the uses being discussed here. Compounded versions exist in the US through certain licensed providers, but their quality, purity, and concentration can vary considerably. A 2023 FDA guidance document flagged several peptides, including BPC-157, as not meeting the criteria for compounding under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Anyone considering peptide therapy should work with a licensed provider who can review their full health history, not take cues from a TikTok conversation.